Log-in / Create Account  
 
DIA 2013 49th Annual Meeting
Click here to go to the previous page
Using Risk-based Signal Detection Methods to Identify Sites with Potential GCP Problems: Better Than a Crystal Ball
Track : Track 19: Communities Showcase
Program Code: 224A
Date: Tuesday, June 25, 2013
Time: 8:00 AM to 9:30 AM  EST
Location: 205 A
SPEAKER (S):
Kay L. Weiler, BSN,JD,MA,RN (SCHNON), Vice President, Compleware, United States
 C. Grant Simmons, MSc (SPKNON), Director, Clinical Systems Innovation, Novartis Pharmaceuticals Corporation, United States
 Ann Meeker-O'Connell, MS (SPKAGY), Senior Director, QA Clinical Strategy Team Lead, Janssen Pharmaceutica Inc., United States
Description
Innovative methods to detect potential GCP noncompliance before, during and/or after clinical trial execution have been developed. This forum discussion will present approaches from FDA and a sponsor.

This forum has been developed by the Good Clinical Practices and Quality Assurance Community.

Session Recording
(Code: 224A)
DIA 2013 Attendee:
Attendees Login
  
This session is a part of:
DIA 2013 Live Learning Center
CON3 Comp Access: Tuesday Online Access Package - June 25, 2013
Handout Online
(Code: 224A)
DIA 2013 Attendee:
Attendees Login
  
This session is a part of:
DIA 2013 Live Learning Center
CON3 Comp Access: Tuesday Online Access Package - June 25, 2013
Using Risk-based Signal Detection Methods to Identify Sites with Potential GCP Problems: Better Than a Crystal Ball